Evidence map›Paper›PMID 36516010›Full record

Trial reportClinical pharmacology in drug development2023

First-in-Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15-Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis.

Lan Gao, Peter Giannousis, Martin Thoolen, Diksha Kaushik, Joey Latham, Aaron Tansy, Jiyuan Ma, Mayzie Johnston, Mandar Dali, Lee Golden and 3 more

Open access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical pharmacology in drug development, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Lan GaoPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Peter GiannousisPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Martin ThoolenPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Diksha KaushikPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Joey LathamPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Aaron TansyPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Jiyuan MaPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Mayzie JohnstonPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Mandar DaliPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Lee GoldenPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Matthew KleinPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Ronald KongPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
Jeffrey TrimmerPTC Therapeutics, Inc., South Plainfield, New Jersey, USA.
PTC Therapeutics (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Utreloxastat (PTC857) is a 15-lipoxygenase inhibitor being developed to treat amyotrophic lateral sclerosis. This first-in-human study investigated the safety and pharmacokinetics of utreloxastat in healthy volunteers (N = 82) in a double-blind, placebo-controlled trial. The effects of a single ascending dose (100-1000 mg), multiple ascending doses (150-500 mg), and food (500 mg) on the pharmacokinetics and safety of utreloxastat were evaluated. Following single doses, the time to maximum plasma concentration (C

Indexed as

Amyotrophic Lateral SclerosisArea Under CurveDouble-Blind MethodHalf-LifeHumansKinetics15-lipooxygenase inhibitorALSamyotrophic lateral sclerosispharmacokineticutreloxastat (PTC857)

Identifiers

PMID36516010
PMCPMC10107758
OpenAlexW4311472854

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.